Group 1 - The core achievement of AI drug development by Heptares Pharmaceuticals is the significant increase in the target hit rate for antibody characterization from 8.7% to 78.5%, with a high purity and expression rate of 21.5% [1] - Heptares Pharmaceuticals has launched the Hu-mAtrIx AI platform, which led to the creation of the first fully human AI HCAb model, enhancing the efficiency and accuracy of antibody discovery through an integrated AI design and validation process [1] - The CEO of Heptares, Dr. Wang Jinsong, emphasized that AI in drug development is transitioning from concept validation to large-scale implementation, becoming a core infrastructure for the competitiveness of pharmaceutical companies over the next decade [1] Group 2 - According to a survey by Define Venture, 70% of major pharmaceutical companies are considering collaboration with external AI tools, indicating a strong trend towards integrating AI into global drug development [2] - Heptares Pharmaceuticals is actively building an AI-driven ecosystem for drug development, having announced the establishment of the AI + Biomedicine Ecosystem Alliance aimed at reshaping the entire drug development process [2] - The company aims to establish an AI-driven automated innovation ecosystem platform by 2028, facilitating the transition from project initiation to clinical trials in biomedicine [2]

Group 1 - The core viewpoint of the report is that due to the upfront payment from the collaboration with BMS, the company has raised its 2026 profit forecast by 228% to USD 0.62 billion and introduced a new profit forecast for 2027 at USD 0.60 billion [1] - The target price has been increased by 34.3% to HKD 18.00, indicating a potential upside of 44.5% from the current stock price [1] Group 2 - The company announced a long-term strategic partnership with Blue Nanotech on December 29, 2025, to advance the development of next-generation radionuclide drug conjugates (RDCs) [2] - The proprietary Harbour Mice platform allows the company to produce fully human monoclonal antibodies in H2L2 and HCAb formats, which have lower immunogenicity, superior tissue penetration, and high specificity and stability, enhancing the efficacy of RDC drugs while reducing side effects [3] - The company has established multiple overseas licensing collaborations, including a long-term global strategic cooperation agreement with BMS on December 17, 2025, which includes an upfront payment of USD 90 million and potential milestone payments of up to USD 1.035 billion [3] - A non-exclusive licensing agreement was signed with Pfizer on November 19, 2025, for advancing preclinical antibody discovery for various potential diseases, with upfront payments and milestone payments based on regulatory, clinical, and commercialization achievements [3] - The collaboration with AstraZeneca was further deepened on November 24, 2025, expanding the scope to include ADC and TCE drugs [3]